Dachaigh › Aillse Sgamhain Neo-chealla-beag › Texas › Austin
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Austin, TX
Tha 30 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Austin (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- NEXT Austin, Austin
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #46, Austin
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A’ fastadhÌre 3
- Texas Oncology-Austin Central, Austin
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- Texas Oncology - South Austin, Austin
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A’ fastadhÌre 3
- Texas Oncology- Central South., Austin
- Texas Oncology Central South, Austin
- Texas Oncology- Central South., Austin
- agus 1 a bharrachd
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Texas Oncology - Central/South Texas, Austin
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Texas Oncology South, Austin
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
A’ fastadhÌre 1/2
- Next Oncology - Austin, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
A’ fastadhÌre 1/2
- Texas Oncology (Balcones) - SCRI, Austin
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A’ fastadhÌre 3
- Clinical Study Site, Austin
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A’ fastadhÌre 2/3
- Local Institution - 007-892-B, Austin
- Local Institution - 007-892-A, Austin
- USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A’ fastadhÌre 1
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- USO - Texas Oncology, Austin
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology Texas, Austin
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
A’ fastadhÌre 3
- Research Site, Austin
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology - Austin, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- Texas Oncology - Central / South Texas, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
A’ fastadhÌre 1
- NEXT Oncology Austin /ID# 243005, Austin
Study of XB010 in Subjects With Solid Tumors
A’ fastadhÌre 1
- NEXT Austin, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A’ fastadhÌre 1
- NEXT Texas LLC - Austin, Austin
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Texas LLC - Austin, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
A’ fastadhÌre 2
- Texas Oncology - Austin Central, Austin
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
A’ fastadhÌre 3
- Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A’ fastadhÌre 1/2
- University of Texas at Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A’ fastadhÌre 1
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 135, Austin
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
A’ fastadhÌre 2
- TxO Central/South, Texas Oncology -Central/South Texas, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A’ fastadhÌre 1/2
- NEXT Austin, Austin
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Austin
- Aillse (gach seòrsa)20 sgrùdaidhean
- Obesity20 sgrùdaidhean
- Aillse colorectal19 sgrùdaidhean
- Ailse metastatach19 sgrùdaidhean
- Ro-throm18 sgrùdaidhean
- Fàilligeadh a' Chridhe18 sgrùdaidhean
- Aillse a' bhroilleach18 sgrùdaidhean
- Cancer Ovarian17 sgrùdaidhean
- Ailse Endometrial15 sgrùdaidhean
- Aillse Prostata15 sgrùdaidhean
- Depression14 sgrùdaidhean
- Schizophrenia13 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.